Levels of Antinuclear and Anti-double Stranded Antibodies in Sera of Breast Cancer Patients

Sadeq K. Hachim¹*, Aesha S. Ali², Mohammed R. Ali³

¹Department of Nursing Technology, Middle Technical University, Institute of Medical Technology,Baghdad, Iraq

²Department of Microbiology, College of Medicine, Ninevah University, Ninevah, Iraq

³Department of Microbiology, College of Medicine, Al-Nahrain University, Baghdad, Iraq

Corresponding Author: [email protected]; [email protected]; Tel: 00964 771 108 3673

Recieved Date: September 22, 2020; Accepted Date: January 23, 2021; Published Date: 03 February 2021

Citation: Hachim SK, Ali AS, Ali MR. Levels of Antinuclear and Anti-double Stranded Antibodies in Sera of Breast Cancer Patients. Trop J Nat Prod Res. 2021; 5(1):62-65.  https://doi.org/10.26538/tjnpr/v5i1.6

Copyright: © 2021 Hachim et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Antinuclear antibodies (ANAs) and anti-double stranded deoxyribonucleic acid antibodies (ADSADs) are autoantibodies that have been linked to biomarkers of systemic autoimmune diseases. Although their involvement in relation to breast cancer is yet to be examined. Therefore, this study evaluated the serum concentration of ANAs and ADSDAs in breast cancer patients, with a view to finding diagnostic biomarkers. One hundred female patients with breast cancer which were recently diagnosed depending on histopathology and hormonal receptor criteria by an oncologist, and another twenty-five females as healthy control group were recruited for the study. Direct interview of the female patients and healthy (control) group was conducted in addition to the information from patients’ registration records in the hospital. An aliquot of 5 mL of intravenous blood was collected from each subject to recover serum samples after centrifugation. An enzyme-linked immunosorbent assay (ELISA) was used to measure the concentrations of ANAs and ADSADs in the sera. The mean age of breast cancer patients was 55.60 years, while that of the healthy control group was 56.76 years. There was a highly significant (P < 0.05) association between ANA of breast cancer patients and grade, as well as stage (MCP < 0.01). On the contrary, the concentration of ADSADs was showing no significant association with the grade (MCP > 0.05) and stage (MCP > 0.05) of breast cancer patients. Conclusively, our findings suggest the use of ANA as a diagnostic biomarker for breast cancer patients.